Despite challenges of rare disease drug development, genetic skeletal disorder (GSD) therapies continue to be developed through novel approaches such as drug repurposing and in-utero stem cell transplants, according to a recent review.
Despite challenges of rare disease drug development, genetic skeletal disorder (GSD) therapies continue to be developed through novel approaches such as drug repurposing and in-utero stem cell transplants, according to recent studies.
Over 140 articles and 80 trials were reviewed by researchers in a study published by Orphanet Journal of Rare Diseases. Specifically, the researchers evaluated literature through a systematic search strategy of government databases.
“Rare bone diseases account for 5% of all birth defects and are an important cause of disability worldwide, yet they remain a difficult group of conditions to treat. In the 2015 Nosology and Classification of Genetic Skeletal Disorders (GSDs) there were 436 GSDs with hundreds of causative genes. Improved understanding of the fundamental pathophysiological pathways in GSDs has accelerated interest in related personalised therapies,” explained the authors.
Researchers identified over 20 personalized therapies as well as several novel disease modifying treatments in over 25 GSDs. They concluded that inherited bone dysplasias often share similar pathophysiological and molecular pathways in altering the body’s bone function. Studying these skeletal disorders assisted in the findings of potential therapeutic options for diseases, noted the authors.
The analysis of the articles and trials discussed several treatments at different stages of development. These included burosumab for X-linked hypophosphatemia, palovarotene for hereditary multiple exosteoses, carbamazepine for metaphyseal chondrodysplasia (Schmid type), lithium carbonate and anti-sclerostin therapy for osteoporosis pseudoglioma syndrome and novel therapies for osteopetrosis.
“As our understanding of the mechanisms involved within the bone mineral unit, conversion of osteoblasts to osteocytes, maturation of osteoclasts, and related mechanisms evolve, new osteoblastic, osteocytic, and osteoclastic therapeutic targets will no doubt emerge,” explained the authors. “Novel approaches like induced pluripotent stem cells, may prove to be pivotal in development of drugs in rare disease.”
The review results suggest the need for increased collaboration among different stakeholders, including academic research centers, pharmaceutical companies, and hospitals, in order to overcome the safety and regulatory issues involved in developing new therapies.
Reference
Sabir AH, Cole T. The evolving therapeutic landscape of genetic skeletal disorders [published online December 30, 2019]. Orphanet J Rare Dis. doi:10.1186/s13023-019-1222-2.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
November 21st 2023Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Odevixibat Safe for Alagille Syndrome Based on Hepatic Changes
November 8th 2023Pooled phase 3 data presented at North American Society for Pediatric Gastroenterology, Hepatology & Nutrition 2023 support the benefit-risk profile of the ileal bile acid transport inhibitor in treating the rare liver disease.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen